Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Suzhou Kintor Pharmaceuticals

Request full access

Kintor is a pharmaceutical research company

ChinaFounded 2009Biotech & Life Sciences

About Suzhou Kintor Pharmaceuticals

Kintor Pharmaceutical, a clinical-stage biopharmaceutical company, was established in Suzhou, China, in 2009. The company was founded by Dr. Youzhi Tong, who currently serves as the Chairman and CEO. Dr. Tong has over 25 years of experience in drug research and development, previously holding the position of Vice President at Angion Biomedica Corp. in the United States and serving as an assistant professor at the Albert Einstein College of Medicine. Kintor Pharmaceutical successfully listed on the Hong Kong Stock Exchange in May 2020.

The company's primary focus is on the research and development of novel drugs for androgen receptor (AR)-related diseases, initially concentrating on oncology indications like prostate, breast, and liver cancer. Its pipeline includes small-molecule drugs, biologics, and combination therapies. Key drug candidates have included Proxalutamide for metastatic castration-resistant prostate cancer and Pyrilutamide (KX-826) for androgenic alopecia and acne. However, after facing setbacks in clinical trials for its oncology and COVID-19 drug candidates, Kintor has strategically shifted its focus. The company is now prioritizing the development and commercialization of treatments for dermatological conditions, such as hair loss and acne. This pivot includes a dual strategy of pursuing regulatory approval for prescription drugs while also marketing over-the-counter cosmetic products to generate early revenue. In 2024, the company recorded its first revenue from its cosmetic brand, Koshiné.

Kintor operates a globally integrated research and development platform with teams in Suzhou, Shanghai, and the United States. To support its commercialization efforts, the company has a modern manufacturing facility in Suzhou Industrial Park, designed in accordance with international GMP standards. This strategic shift towards dermatology and cosmetics aims to leverage their expertise in the AR signaling pathway while navigating the capital-intensive nature of oncology drug development. The company is developing both topical and oral drug candidates and is also exploring the commercialization of functional raw materials for cosmetics, such as for skin whitening and freckle removal.

Source: Dealroom company data

At a glance

Status
Operational
Employees
32
Open positions
None listed
Dealroom signal
48.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Oct 2019 $45M $180M Highlight Capital · CCB International · FTZ Fund —
SERIES COther financing Jan 2018 $44M $176M Green Pine Capital —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Suzhou Kintor Pharmaceuticals website traffic

Latest recorded traffic for Suzhou Kintor Pharmaceuticals is 10K monthly website visits, down 37.5% over the last three months. Suzhou Kintor Pharmaceuticals's team grew 14.3% over the past year.

Latest monthly visits10K 3-month web change-37.5% 1-year team growth+14.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Suzhou Kintor Pharmaceuticals in its local ecosystem

Live from Dealroom

The Suzhou Kintor Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later4 investors entered at this stage

  • Green Pine Capital
  • FTZ Fund
  • Highlight Capital
  • CCB International
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States50%
🇨🇳 China50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Suzhou Kintor Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Suzhou Kintor Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.